seen from United States
seen from China
seen from United States
seen from Türkiye
seen from United States
seen from United Kingdom
seen from United Kingdom
seen from Kazakhstan
seen from United Kingdom
seen from Germany
seen from United States
seen from United Kingdom
seen from United States
seen from United States
seen from United Kingdom
seen from United States
seen from Australia
seen from United States
seen from Latvia
seen from United States
FDA Authorizes More Medical Devices in 2026 Amid Longer Reviews
The U.S. Food and Drug Administration authorized a higher number of medical devices in the first half of 2026 compared with the same period in 2025. Review timelines for original premarket approvals lengthened substantially during this period. The trend emerges as the agency prepares for a public meeting on August 5, 2026, regarding future medical device user fee commitments. In Silver Spring,…
View On WordPress
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
FasterCures commends bipartisan support of FDA Reauthorization Act
FasterCures, a Center of the Milken Institute, commends the U.S. Senate on today’s strong, bipartisan support of the U.S. Food and Drug Administration (FDA) Reauthorization Act (FDARA) (H.R. 2430), which passed the Senate on a 94-1 vote, matching the U.S. House of Representatives’ passage on July 12, via voice vote. The bill will now be sent to the White House.
Beginning with the first public meetings back in July 2015, FasterCures has been an active participant in the stakeholder meetings for both the Prescription Drug User Fee Act (PDUFA) and the Medical Device User Fee Amendments (MDUFA). Throughout the process, FasterCures advocated for inclusion of provisions designed to enhance and advance FDA’s efforts to deepen and expand engagement with the patient community. We were very pleased to see those priorities reflected in the commitment letters for both MDUFA and PDUFA. In addition, FDARA – and PDUFA in particular – will provide critical resources to help FDA address the persistent challenge of recruiting and maintaining a workforce of highly trained scientists, clinicians, statisticians, and engineers. We look forward to continuing to work with FDA and other stakeholders to help implement and advance the provisions of this key legislation.
